Communicated by Robert C. Gallo, January 2, 1992 (received for review July 5, 1991) ABSTRACT Modified bovine leukemia virus (BLV) glycoproteins were expressed by using vaccinia virus recombinants, and their fusogenic capacities were examined by a syncytia-formation assay. This analysis indicates that (s) both BLV envelope glycoproteins gp5l and gp3O are necessary for cell fusion; (ii) insertion of the N-terminal segment of gp3O (fusion peptide) into the lipid bilayer in an oblique orientation, as predicted by computer conformational analysis, results in fusogenic capacities higher than insertion in a perpendicular or parallel orientation; and (iii) replacement of the BLV fusion
peptide with its simian immunodeficiency virus counterpart does not modify the fusogenic capacity ofthe BLV glycoprotein.
The molecular mechanisms involved in membrane fusion are not well known. Mutational analyses on the envelope genes of various retroviruses, such as human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV), have indicated that the N-terminal segment of the transmembrane region (fusion peptide) of the viral envelope glycoprotein is involved in membrane fusion (1) (2) (3) . Computer conformational analyses on the fusogenic segment of HIV and Newcastle disease virus envelope glycoproteins have led to the hypothesis that the fusion peptide is obliquely oriented at the lipid-water interface, thereby inducing a local membrane destabilization and promoting cell fusion (4, 5) . This hypothesis has also been extended to several other viral systems that display fusogenic properties (6) , including bovine leukemia virus (BLV).
BLV is the etiological agent of enzootic bovine leucosis, the most frequent bovine neoplastic disease. The BLV envelope glycoprotein is synthesized as a 72-kDa (gp72) precursor polypeptide that is proteolytically processed into the 51-kDa (gpSl) and 30-kDa (gp3O) mature forms by a cellular protease. gpSl is the external subunit containing the cell receptor-binding domain, and gp3O is the transmembrane subunit that anchors the gpSl-gp3O complex in the plasma membrane of infected cells and the viral envelope obtained by viral budding from the infected cell (7) . This BLV envelope glycoprotein complex is essential to infection and syncytium induction, as demonstrated by the ability of polyclonal sera (8) and some monoclonal antibodies (mAbs) (9) directed against gpSl to inhibit BLV-induced cell fusion.
We show here that orientation of the fusogenic segment of the BLV envelope glycoprotein in the lipid bilayer is critical for membrane fusion. When the fusion peptide is inserted in the lipid bilayer obliquely, fusion capacity is higher than when the peptide is inserted in a perpendicular or parallel orientation. In addition, we show that the BLV fusion peptide can be replaced by its SIV counterpart without modification of the fusogenic capacity.
MATERIALS AND METHODS
Cloning of BLV Envelope Gene in M13 Phage and DNA Mutagenesis. A recombinant A gtlO phage containing the BLV envelope sequence was obtained from a cDNA library constructed from total RNA from bat lung cells producing BLV (10) . A Xho I-Xho I fragment was excised from the recombinant phage and subcloned into the Sal I site of plasmid vector pSP64, giving pSP64-ENV.
A BamHI-HindIII fragment containing the BLV envelope sequence was excised from pSP64-ENV and subcloned into phage M13mpl8, giving M13-ENV. Single-stranded DNA from this phage was used as template for in vitro mutagenesis, following Amersham protocols based on the Eckstein method (11, 12) .
Construction of Vaccinia Virus (W) Donor Plasmids. An EcoRI-HindIII fragment was excised from each M13-ENV mutant phage (MUO-MU5), filled with Escherichia coli DNA polymerase I (Klenow fragment), and cloned into the Sma I site of the VV insertion vector pSC11, giving pSC11-MUO to -MU5 (pSC11 was obtained from B. Moss, National Institutes of Health). The complete sequence of the modified gpSl and gp3O genes was then determined to verify the presence of the introduced mutations and to check for the absence of unwanted modifications.
A BamHI-HindIII fragment containing the wild-type BLV envelope sequence was excised from pSP64-ENV, filled with Klenow fragments, and cloned into the Sma I site of pSC11, giving pSC11-ENV. pSC11 and all constructions derived from it use the VV promoter p7.5.
Construction of W Recombinants. The procedures used to isolate VV recombinants have been described (13, 14) .
Cells, Viruses, and mAbs. Wild-type VV (Elstree strain) and recombinants derived from it were propagated in CV1 cells. VV recombinants vP391 and vP482, encoding gpSl and uncleaved gp72, respectively, have been described (15) . The BLV gpSl-specific mAbs (mono A, B, B', C, D, D', E, F, G, and H) have been described (9) .
ELISA. ELISA determinations to measure recombinant VV infected cell extracts were done as described (16 (18) .
Syncytia-Formation Assay. Two methods were used: (i) VERO cells, grown in 96-well plates (10,000 cells per well), were infected with recombinant VV at multiplicity of infection of 1 plaque-forming unit per cell and cocultivated with CC81 cells (40,000 cells per well) 6 hr after infection. Twentyfour hours after infection, cells were washed and fixed. Syncytia were counted microscopically in six different fields at x400. Fifty cells were counted per field, and multinucleated cells containing more than four nuclei were considered to be syncytium; (ii) CV1 cells (50,000 cells per well) were infected with recombinant VV at a multiplicity of infection of 1 plaque-forming unit per cell. Twenty-four hours later, cells were treated as described in i.
Fusion-Inhibition Assay. CV1 or VERO cells were incubated with dilutions (1:3, 1:9, 1:27, 1:81, 1:243, and 1:729) of a BLV gpS1-specific mAb to epitope H and after infection with various recombinant VVs were analyzed for syncytia formation as described above.
Conformational Analysis. The method used to predict conformational structure of the fusion peptide accounts for the contribution of the lipid-water interface, the concomitant variation of the dielectric constant, and the transfer energy of atoms from a hydrophobic to hydrophilic environment (19) . The structure, mode of insertion, and orientation of the fusogenic peptide were studied in a dipalmitoylphosphatidylcholine molecular layer (20) . In this model, the interaction energy (sum of contributions from Van der Waals energy interactions, torsional potential energy, electrostatic interactions, and transfer energy between fusogenic peptide and dipalmitoylphosphatidylcholine in the monolayer) is considered and minimized until the lowest energy state of the entire aggregate is reached. We limit this approach to the number of lipids sufficient to surround the peptide, and we keep the structure of molecules (lipids and peptide) frozen during the process of assembly (6, 21, 22) . All calculations were made on an Olivetti CP486, by using PC-TAMMO+ (Theoretical Analysis of Molecular Membrane Organization) and PC-PROT+ (Proteins Plus Analysis) software. Graphs were drawn with the PC-MGM + (Molecular Graphics Manipulation) program.
RESULTS
Both gp5l and gp3O Are Required for Cell Fusion Activity. To study the role that various regions of the BLV envelope glycoprotein have in membrane fusion, recombinant VVs containing modified BLV envelope genes were constructed. A recombinant virus, vP391, containing BLV gp5l without gp3O was constructed to study the importance of gp3O in fusogenic activity of the BLV envelope gene product (15) . Another recombinant virus, vP482, containing an envelope gene mutated at the cleavage site (amino acids 268 and 269 converted from Arg-Ser to Gln-Thr) was constructed to determine whether processing ofthe envelope gp72 precursor glycoprotein into mature gp5l and gp3O forms is required for fusogenic activity (15) . As a control, a recombinant ENV containing a wild-type BLV envelope gene was also constructed.
To verify that vP391 and vP482 express and process the modified BLV envelope glycoproteins correctly, immunoblot analysis was done (Fig. 1 ). This immunoblot shows that cells infected with vP391 and vP482 express proteins with Lysates of recombinant VV-infected CV1 cells were subjected to SDS/PAGE (12.5%), blotted, and incubated with a mixture of mAbs against gp5l (A, B, B', C, D, and E). WT, nonrecombinant VV; CV1, uninfected CV1 cells. Positions of gp72 and gpSl glycoproteins are indicated at left. molecular masses of -50 and 70 kDa, respectively. Immunoblots were also prepared from supernatants of the infected cultures. These blots indicate that more gpSl appears in the supernatant of vP391-infected cells than in the supernatant of ENV-infected cells (data not shown), suggesting that gp5l is shed at a higher rate when expressed without the gp3O transmembrane domain than when gpSl is expressed with gp3O.
To determine whether gp5l is expressed at the cell surface, indirect immunofluorescence with a mixture of mAbs against gpSl was done (Fig. 2) . These studies show that ENV and vP482-infected cells express gp5l on their surface, suggesting that the intracellular transport of gp5l to the plasma membrane is not affected by a lack of cleavage of the gp72 precursor glycoprotein. However, the amount of gp5l detected at the surface of vP391-infected cells was low in comparison with ENV-infected cells, suggesting once again that gpSl is secreted into the supernatant at a higher rate in cells infected with vP391 than in cells infected with a recombinant expressing wild-type gp5l and gp3O.
The antigenic structure of the glycoprotein produced in vP391-and vP482-infected cells was examined by using an ELISA with mAbs against the gp5l conformational epitopes F, G, and H (Fig. 3) . These results show that the F, G, and H epitopes are weakly recognized on the uncleaved gp72 precursor produced in vP482-infected cells. This result indicates that the affinity of the mAbs monoF and monoH for gp72 is reduced relative to their affinity for the glycoprotein produced in ENV-infected cells. This observation is consistent with previous results showing that the absence of cleavage affects the generation of native gp5l (15) . ELISA data also reveal that epitopes F and H are weakly recognized on the glycoprotein produced in vP391-infected cells. This result, however, may be from the elevated levels of gpSl shed in cells infected by this recombinant virus.
ENV, vP391, and vP482 were tested for their ability to fuse in two cell culture systems (Table 1 and Fig. 2) . These experiments reveal that vP391 cannot induce syncytia, suggesting an important role for gp3O in membrane fusion. These results also show that the fusogenic activity of vP482 is very weak (10%) relative to ENV, indicating that the absence of cleavage of gp72 affects fusogenic activity of the BLV envelope gene product.
Inhibition of syncytia formation by a neutralizing antibody against the conformational epitope H of gpSl was examined for vP482 (Table 1 ). The fusogenic activity of vP482 is completely inhibited by monoH serum, as it is for ENV, indicating that the H epitope plays a crucial role in syncytia formation, despite the reduced affinity of monoH for this epitope.
Theoretical Analysis of BLV Fusion Peptide. To create a model of the interaction between the BLV fusion peptide within the lipid bilayer, computer-aided conformational analyses were done. The amino acid sequence of the BLV gp72 precursor has been analyzed according to Eisenberg et al. (23, 24) . The region immediately after the cleavage site of gp72 contains a hydrophobic protein segment called the fusion peptide. There is a high probability that the BLV fusion peptide will adopt a helical structure after its insertion into a lipid bilayer (5, 25, 29) . Two major types of helical structures have been identified so far in proteins that associate with lipids: amphipathic helices that lie at the surface of the lipid phase, and the helical configurations oriented in parallel to the lipid acyl chains adopted by transmembrane domains. A conformational analysis of the first 12 amino acids of BLV gp3O, as described (4) for gp4l of HIV, shows that the BLV fusogenic peptide orients obliquely with a 600 angle relative to the lipid-water interface and exhibits membrane-destabilizing properties. The precision of prediction of the peptide orientation is equal to 50 and is due to the method used (6, 21, 22 peptide predicted to insert into the lipid bilayer in either one of three different orientations: perpendicular, parallel, or oblique (Table 1) .
In MUO, three amino acid substitutions (Leu-Ala-Leu converted to Arg-Asp-Arg) were introduced at the C terminus of the fusion peptide, producing a fusion peptide with a theoretical insertion angle of 870. In MU1, amino acids 1 and 4 were changed (Ser-1 converted to leucine and Ala-4 converted to leucine), producing a fusion peptide with a theoretical insertion angle of40. In MU2, amino acids 1 and 5 were changed (Ser-1 converted to leucine and Ala-5 converted to leucine), producing a fusion peptide with a theoretical insertion angle of 310. In MU3, amino acids 4 and 7 were changed (Ala-4 converted to leucine and Thr-7 converted to serine), producing a fusion peptide with a theoretical insertion angle of 85°. In MU4, amino acids 5 and 7 were changed (Ala-5 converted to leucine and Thr-7 converted to serine), producing a fusion peptide with a theoretical insertion angle of 68°. (MU1 and MU2 as well as MU3 and MU4 were designed to have identical global hydrophobicities, yet different theoretical angles of insertion. High hydrophobicity values indicate a high affinity for the lipid bilayer, and low values indicate a low affinity for the lipid bilayer.) Fig. 4 illustrates the mode of insertion in the lipid matrix of the wild-type BLV fusion peptide (ENV) and the two mutants (MU1 and MUO) that mimic the major types of membrane helical structures, amphipathic and transmembrane protein domains. Fig. 4 illustrates that the highest theoretical membrane-destabilizing capacity is induced by the wild-type fusion peptide (ENV).
Another recombinant virus, MU5, was constructed to study specificity of the BLV and SIV fusion peptides. In this recombinant, the BLV fusion peptide is replaced by its SIV counterpart. The theoretical angle of insertion of the fusion peptide of MU5 is 530 (Table 1) .
To verify that these recombinant viruses express and process the modified BLV envelope glycoproteins correctly, immunoblot analysis was done (Fig. 1) . This analysis reveals that cells infected with MUO-MU4 express proteins with molecular masses of "50 kDa, indicating that the mutations in these recombinants do not affect expression or processing of the modified envelope glycoproteins. This analysis did show, however, that the cleavage efficiency of gp72 in MU5-infected cells is altered.
To determine whether gpSl is expressed at the cell surface, indirect immunofluorescence by using a mixture of mAbs against gp5l was done (Fig. 2) . This tFusion inhibition was seen in a syncytia-formation assay after incubation with anti-gp5l mAbs. Fusion inhibition was expressed as serum titers (reciprocal dilution giving 50o inhibition).
tHydrophobicity means were computed according to the Eisenberg consensus scale (21) .
cells expressed gpSl on their surface and that the intracellular transport of gp5l to the plasma membrane is not affected by the modifications of the gp30 fusion peptide. The antigenic structure of the gpSl glycoprotein produced in cells infected with these recombinant viruses was then examined in an ELISA, with mAbs against the gpSl conformational epitopes F, G, and H (Fig. 3) . The antigenic structure of the glycoproteins produced in MUO-to MU5-infected cells is not altered by the amino acid substitutions introduced into the gp30 fusogenic segment.
MUO-MU5 were then tested for their fusogenic capacity in two cell culture systems (Table 1 and Fig. 2 ). The fusogenic activity of MUO, MU1, MU2, and MU3 is reduced (17%, 15%, 23%, and 18%, respectively) relative to ENV, but MU4 and MU5 induce efficient fusion (86% and 100%, respectively).
Inhibition of syncytia formation by a neutralizing antibody against the conformational epitope H of gpSl was examined in these recombinant viruses ( Table 1 ). The fusogenic activities of MUO, MU1, MU2, MU3, MU4, and MU5 are inhibited by similar titers of monoH serum as ENV, indicating that the antigenic structure of the glycoproteins produced in cells infected with these recombinant viruses is not significantly altered with respect to the wild-type gpSl-gp3O complex.
DISCUSSION
Studies done on the envelope glycoprotein of syncytiainducing retroviruses, such as HIV and SIV, have suggested that the N-terminal segment of the transmembrane glycoprotein is involved in membrane fusion (1) (2) (3) . Corresponding structures have also been found in myxo-and paramyxoviruses (26, 28) . This communication reports on the molecular aspects of the fusogenic activity of the BLV envelope glycoprotein.
Our results indicate that both the gpSl and gp3O components of the BLV envelope gene product are important for fusogenic activity. A VV recombinant, vP391, expressing gpSl alone had no fusion activity. Further experiments with this recombinant showed that the conformational epitopes F and H were weakly represented, suggesting that conformational changes in gpSl had occurred. Thus, the native configuration of gpSl appears to depend upon an interaction between gpSl and gp3O, and both glycoproteins are necessary for cell fusion.
Furthermore, cleavage of the gp72 precursor glycoprotein into mature gpSl and gp3O forms is also important for inducing fusion. A VV recombinant, vP482, expressing an uncleaved form of BLV glycoprotein exhibited weak fusogenic activity, suggesting that cleavage of gp72 precursor glycoprotein is necessary for fusion. These observations are consistent with results obtained by McCune et al. (27) , in which an HIV variant expressing an uncleaved form of gpl60 was deficient in both infectivity and cell fusion activity.
The decreased fusogenic activity of vP482 does not appear to be due to its lower expression because the uncleaved gp72 glycoprotein was expressed at the cell surface of infected cells at apparently the same level as the wild-type glycoprotein. This decrease most likely is from a conformational change in gp72 glycoprotein. This hypothesis is consistent with the ELISA data, indicating that gp72 reactivity to mAbs against conformational epitopes F and H was significantly Microbiology: Vone'che et al. reduced. Thus, the conformational integrity of gp51 and gp30 is apparently important for fusogenic activity.
In the second part of our study, amino acid substitutions were introduced in the fusion domain of gp30. These substitutions were made to modify the orientation of the fusion peptide relative to the lipid bilayer.
The VV recombinants MU0, MUL, and MU3 exhibited very weak fusogenic activities. Based on theoretical calculations, the fusion peptides of these three recombinants minimally disturb the lipid bilayer. The fusion peptides of the recombinants MUO and MU3 were designed to align in parallel with the lipid acyl chains (angles of insertion are 870 and 850, respectively), and the fusion peptide of recombinant MU1 was designed to align perpendicularly to the lipid acyl chains (angle of insertion is 4°). The fusogenic activity of these recombinants is consistent with the hypothesis that fusion requires disruption of the dynamic stability of the lipid bilayer, a state highly favored by the oblique insertion of a peptide helical structure (4, 5) .
The recombinant MU4 had fusogenic activity of 86%. This recombinant was constructed so that the fusion peptide would be inserted into the lipid bilayer obliquely (angle of insertion was 680). Mutations in MU4, therefore, had little effect on syncytia formation, suggesting that insertion of the fusion peptide in the lipid bilayer in an oblique orientation is important for membrane fusion.
Recombinants MU3 and MU4 have the same global hydrophobicity; their theoretical orientation in the membrane, however, differs significantly. The fusion peptide of MU3 was predicted to be inserted into the lipid-water interface at a perpendicular angle. The fusion peptide of MU4 was predicted to be inserted obliquely. Because MU3 has a fusogenic activity of 18%, and MU4 has a fusogenic activity of 86%, it appears that together with the global hydrophobicity of the fusion peptide, oblique insertion is a major prerequisite for fusion efficiency.
The fusion peptide of recombinant MU2 was predicted to be inserted into the lipid bilayer in an oblique orientation. The fusogenic capacity of this recombinant, however, is very low (23%). This result is surprising and suggests that, in addition to being inserted into the lipid bilayer in an oblique orientation, the angle of insertion of the fusion peptide is important. [ The angle of insertion of the MU2 fusion peptide (310) is considerably lower than the angle of insertion of the wildtype fusion peptide (600).]
The different fusogenic capacities of recombinants MU0, MU1, MU2, MU3, and MU4 support our hypothesis that insertion of the BLV fusion peptide in the lipid bilayer at an oblique angle is necessary, but not sufficient, for membrane fusion. Similar results were also obtained with the fusion peptide of the SIV transmembrane glycoprotein gp32 (30) .
A VV recombinant was also constructed in which the BLV fusion peptide was replaced by its SIV counterpart. The fusogenic capacity of this recombinant, MU5, is 100%. Therefore, the presence of the first 12 amino acids of SIV gp32 at the N terminus of BLV gp3O did not affect the fusogenic activity of the BLV envelope glycoprotein, even though the amino acid sequence of these two fusion peptides is totally different. This result is consistent with the observation that very different amino acid sequences can adopt similar structures in a lipid environment (the angle of insertion of MU5 fusion peptide is 600, as compared with 530 for SIV fusion peptide) and can exhibit similar fusogenic activities (5, 25, 26) .
In conclusion, our results provide insight into the fusion process of BLV by showing the importance of the orientation in the lipid bilayer of the N-terminal peptide of gp3O.
